PreventiveMD vs MEDVi
An all-in floor against a membership that does not name the drug price.
PreventiveMD
Editorial
$83/mo
Two compounded lines described as all-in, at $83 for semaglutide and $97 for tirzepatide by injection. Both are qualified as 'as low as', so both are floors rather than rates, and the dose that sits at the floor is not stated. The $49 monthly membership PreventiveMD charges belongs to its brand plans and does not attach to these two lines. Coverage is stated across 36 states.
Pick it for: Buyers who need the full figure before paying anything
MEDVi
Editorial
$249/mo
One line priced as a price and two priced as a membership. Compounded semaglutide by injection is a flat $249 with no introductory discount shown, while the oral semaglutide and tirzepatide lines publish $99 as a membership fee and state the medication cost separately without naming it. Coverage is stated across 48 states.
Pick it for: Buyers who only want MEDVi's injection line, which does carry one figure
Our verdict
PreventiveMD publishes $83 described as all-in; MEDVi's comparable lines publish a $99 membership and leave the medication cost unstated. One is a price, the other is an entry fee.
What actually separates them
PreventiveMD and MEDVi state different things about published price and where you can use it. Everything else they publish, they publish the same way.
MEDVi costs $166 more than PreventiveMD — 200% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $996 at PreventiveMD against $2,988 at MEDVi — a difference of $1,992.
| PreventiveMD | MEDVi | |
|---|---|---|
| Published price | $83/mo | $249/mo |
| Where you can use it | 36 states | 48 states |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.